Sanuwave Health (SNWV) Expected to Announce Quarterly Earnings on Friday

Sanuwave Health (NASDAQ:SNWV) is anticipated to announce its Q2 2026 results before the market opens on Friday, August 14th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $11.50 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 7, 2026 at 8:30 AM ET.

Sanuwave Health (NASDAQ:SNWV) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.05). The firm had revenue of $9.74 million for the quarter, compared to analysts’ expectations of $11.50 million. Sanuwave Health had a return on equity of 8,163.31% and a net margin of 32.38%.

Sanuwave Health Stock Performance

NASDAQ SNWV opened at $5.50 on Wednesday. The company has a debt-to-equity ratio of 8.15, a current ratio of 1.31 and a quick ratio of 0.99. The stock’s 50 day simple moving average is $9.30 and its 200-day simple moving average is $16.62. The company has a market cap of $47.30 million, a PE ratio of 22.92 and a beta of 1.48. Sanuwave Health has a 1-year low of $5.27 and a 1-year high of $45.33.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Sanuwave Health in a report on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $51.00.

Institutional Trading of Sanuwave Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Praetorian PR LLC grew its stake in shares of Sanuwave Health by 1,436.2% in the fourth quarter. Praetorian PR LLC now owns 265,000 shares of the company’s stock valued at $7,908,000 after buying an additional 247,750 shares in the last quarter. Stifel Financial Corp acquired a new position in Sanuwave Health during the 4th quarter worth about $5,291,000. Geode Capital Management LLC acquired a new position in Sanuwave Health during the 2nd quarter worth about $5,184,000. Lazard Asset Management LLC purchased a new position in Sanuwave Health during the 2nd quarter valued at about $738,000. Finally, Jane Street Group LLC purchased a new position in Sanuwave Health during the 4th quarter valued at about $587,000. Hedge funds and other institutional investors own 42.53% of the company’s stock.

About Sanuwave Health

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.